---
schema_version: "secwatch.filing_event.v1"
accession: "0001674930-26-000025"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2026-05-21T21:04:12+00:00"
generated_at: "2026-05-21T21:10:00.373936+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS

## Summary
- Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.
- Median DoR 7.4 months; 56% of responders still responding at Dec 20, 2025 cut-off; OS immature.
- Favorable safety: mostly Grade 1-2 TRAEs; Grade 3-4 neutropenia, anemia, leukopenia; one Grade 5 pneumonia (Arm B).
- Abstract #6020 presented at ASCO 2026 Rapid Oral Session on June 1, 2026 in Chicago.
- Company notes historical standard-of-care offers ORR 5.8%-19.1% and PFS 2.3-3.7 months in R/M HNSCC.

## SEC filing metadata
- accession: 0001674930-26-000025
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2026-05-21T21:04:12+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000025/0001674930-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000025/flgt-20260521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001674930-26-000025
- JSON: https://secwatch.observer/filing/0001674930-26-000025.json
- Plain text: https://secwatch.observer/filing/0001674930-26-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.